| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| K V Praveen Kumar, P Chiranjeevi, Md Shahid Ala. Aripiprazole-induced transient myopia: A rare entity. Indian journal of ophthalmology. vol 66. issue 1. 2018-04-27. PMID:29283140. |
a 22-year-old female patient presented to the department of psychiatry with worsening of symptoms of schizophrenia and was started on aripiprazole. |
2018-04-27 |
2023-08-13 |
Not clear |
| Jaime M Monti, Pablo Torterolo, Seithikurippu R Pandi Peruma. The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. Sleep medicine reviews. vol 33. 2018-04-24. PMID:27321864. |
to date, no polysomnographic studies have been published on the effects of aripiprazole, asenapine, iloperidone and lurasidone on sleep in either healthy subjects or patients with schizophrenia. |
2018-04-24 |
2023-08-13 |
human |
| Chi-Un Pae, Sheng-Min Wang, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Alessandro Serretti, Robin Emsle. Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. International clinical psychopharmacology. vol 32. issue 5. 2018-04-20. PMID:28430670. |
comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. |
2018-04-20 |
2023-08-13 |
Not clear |
| Chi-Un Pae, Sheng-Min Wang, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Alessandro Serretti, Robin Emsle. Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. International clinical psychopharmacology. vol 32. issue 5. 2018-04-20. PMID:28430670. |
we investigated the relative efficacy and tolerability of aripiprazole once monthly (aom) versus paliperidone palmitate (pp) for treating schizophrenia. |
2018-04-20 |
2023-08-13 |
Not clear |
| Renata Cristina Mendes Ferreira, Ana Flávia Almeida-Santos, Igor Dimitri Gama Duarte, Daniele C Aguiar, Fabricio A Moreira, Thiago Roberto Lima Romer. Peripheral Antinociception Induced by Aripiprazole Is Mediated by the Opioid System. BioMed research international. vol 2017. 2018-04-17. PMID:28758123. |
aripiprazole is an antipsychotic drug used to treat schizophrenia and related disorders. |
2018-04-17 |
2023-08-13 |
Not clear |
| Marjie L Hard, Richard J Mills, Brian M Sadler, Angela Y Wehr, Peter J Weiden, Lisa von Moltk. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. CNS drugs. vol 31. issue 7. 2018-04-12. PMID:28597226. |
aripiprazole lauroxil (al) is a long-acting injectable medication approved for the treatment of schizophrenia. |
2018-04-12 |
2023-08-13 |
Not clear |
| Rene S Kahn, Amalia Giannopoulo. The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. Expert review of neurotherapeutics. vol 15. issue 9. 2018-04-10. PMID:26289486. |
the safety, efficacy and tolerability of abilify maintena for the treatment of schizophrenia. |
2018-04-10 |
2023-08-13 |
Not clear |
| Taichiro Togo, Toshiya Taniguchi, Yoshitaka Nakat. The Effect of Compaction Force on the Transition to Hydrate of Anhydrous Aripiprazole. Chemical & pharmaceutical bulletin. vol 66. issue 3. 2018-03-27. PMID:29491260. |
aripiprazole (apz) is used to treat schizophrenia and is administered as a tablet containing the anhydrous form of apz. |
2018-03-27 |
2023-08-13 |
Not clear |
| Kulothungan Gunasekaran, Swetha Murthi, Jeffrey Jennings, Nazir Lon. Aripiprazole-induced hypersensitivity pneumonitis. BMJ case reports. vol 2017. 2018-03-05. PMID:28487307. |
aripiprazole is an atypical antipsychotic agent commonly used in the management of schizophrenia. |
2018-03-05 |
2023-08-13 |
Not clear |
| Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Timothy Peters-Strickland, Maud Beillat, Anna-Greta Nylander, Peter Hertel, Simon Nitschky Schmidt, Anna Eramo, Karina Hansen, Dieter Nabe. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate. The international journal of neuropsychopharmacology. vol 20. issue 1. 2018-02-13. PMID:27927736. |
multidimensional assessment of functional outcomes in schizophrenia: results from qualify, a head-to-head trial of aripiprazole once-monthly and paliperidone palmitate. |
2018-02-13 |
2023-08-13 |
Not clear |
| Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Timothy Peters-Strickland, Maud Beillat, Anna-Greta Nylander, Peter Hertel, Simon Nitschky Schmidt, Anna Eramo, Karina Hansen, Dieter Nabe. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate. The international journal of neuropsychopharmacology. vol 20. issue 1. 2018-02-13. PMID:27927736. |
qualify was a 28-week, randomized, open-label, head-to-head trial that assessed improvements across multiple measures in stable patients with schizophrenia with aripiprazole once-monthly 400 mg vs paliperidone palmitate. |
2018-02-13 |
2023-08-13 |
Not clear |
| Bart Remmerie, Marc De Meulder, Jay Ariyawansa, Adam Savit. Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole. Clinical pharmacology in drug development. vol 5. issue 6. 2018-01-29. PMID:27363344. |
this open-label, parallel-group study was performed to compare finger-stick-based capillary with corresponding venous plasma concentrations for risperidone, paliperidone, quetiapine, olanzapine, and aripiprazole and their major metabolites after repeated dosing in patients with schizophrenia or related illnesses. |
2018-01-29 |
2023-08-13 |
Not clear |
| Bart Remmerie, Marc De Meulder, Sveta Weiner, Adam Savit. Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole. Clinical pharmacology in drug development. vol 5. issue 6. 2018-01-29. PMID:27365164. |
risperidone, paliperidone, quetiapine, olanzapine, and aripiprazole are antipsychotic drugs approved for treating various psychiatric disorders, including schizophrenia. |
2018-01-29 |
2023-08-13 |
human |
| Bruno Falissard, Christophe Sapin, Jean-Yves Loze, Wally Landsberg, Karina Hanse. Defining the minimal clinically important difference (MCID) of the Heinrichs-carpenter quality of life scale (QLS). International journal of methods in psychiatric research. vol 25. issue 2. 2018-01-16. PMID:26238598. |
data from the "schizophrenia trial of aripiprazole" (star) study were used in this analysis. |
2018-01-16 |
2023-08-13 |
Not clear |
| Mantana Kittipeerachon, Warawat Chaicha. Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial. Schizophrenia research. vol 176. issue 2-3. 2018-01-02. PMID:27461399. |
intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: a pragmatic double-blind randomized trial. |
2018-01-02 |
2023-08-13 |
Not clear |
| Mantana Kittipeerachon, Warawat Chaicha. Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial. Schizophrenia research. vol 176. issue 2-3. 2018-01-02. PMID:27461399. |
to evaluate and compare the effectiveness and adverse effects of intramuscular (im) olanzapine and im aripiprazole for the treatment of agitated patients with schizophrenia in clinical practice. |
2018-01-02 |
2023-08-13 |
Not clear |
| Steven D Targum, Robert Risinger, Yangchun Du, J Cara Pendergrass, Hassan H Jamal, Bernard L Silverma. Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia. Schizophrenia research. vol 179. 2017-12-27. PMID:27707530. |
we conducted a post hoc age and gender analysis of treatment response to aripiprazole lauroxil (al; aristada®; alkermes, inc.), in a 12-week, double-blind, placebo-controlled, multinational, phase 3 study evaluating two doses of al (441mg and 882mg) versus placebo in adult patients experiencing an acute exacerbation of schizophrenia within the previous 2months. |
2017-12-27 |
2023-08-13 |
Not clear |
| Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Timothy Peters-Strickland, Maud Beillat, Anna-Greta Nylander, Peter Hertel, Henrik Steen Andersen, Anna Eramo, Karina Hansen, Dieter Nabe. Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY. International clinical psychopharmacology. vol 32. issue 3. 2017-12-18. PMID:28252452. |
in qualify, a randomized study, aripiprazole once-monthly 400 mg (aom 400), a dopamine d2 receptor partial agonist, showed noninferiority and subsequent superiority versus paliperidone palmitate (pp), a dopamine d2 receptor antagonist, on the heinrichs-carpenter quality-of-life scale (qls) in patients with schizophrenia aged 18-60 years. |
2017-12-18 |
2023-08-13 |
Not clear |
| Goyo Nagai, Kazuo Mihara, Akifumi Nakamura, Kenji Nemoto, Shoko Kagawa, Takeshi Suzuki, Tsuyoshi Kond. Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1. Therapeutic drug monitoring. vol 39. issue 1. 2017-11-28. PMID:27861318. |
prediction of an optimal dose of aripiprazole in the treatment of schizophrenia from plasma concentrations of aripiprazole plus its active metabolite dehydroaripiprazole at week 1. |
2017-11-28 |
2023-08-13 |
Not clear |
| Goyo Nagai, Kazuo Mihara, Akifumi Nakamura, Kenji Nemoto, Shoko Kagawa, Takeshi Suzuki, Tsuyoshi Kond. Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1. Therapeutic drug monitoring. vol 39. issue 1. 2017-11-28. PMID:27861318. |
it has been suggested that a plasma trough concentration of aripiprazole plus its active metabolite, dehydroaripiprazole of 225 ng/ml is a threshold for a good therapeutic response in the treatment of acutely exacerbated patients with schizophrenia. |
2017-11-28 |
2023-08-13 |
Not clear |